NCT04101045 is a NA clinical trial of Oral Glucose Tolerance Test in Type 1 Diabetes, sponsored by Yale University.

Who is sponsoring NCT04101045?

NCT04101045 is sponsored by Yale University.

What drugs are being tested in NCT04101045?

Interventions in NCT04101045: Oral Glucose Tolerance Test.

What condition does NCT04101045 study?

NCT04101045 studies Type 1 Diabetes, De Novo Lipogenesis.

Is NCT04101045 still recruiting?

NCT04101045 is currently terminated. Last updated 13 February 2023.

Last reviewed 2023-02-13 · How we verify

NCT04101045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

Terminated NA Last updated 13 February 2023

What this trial tests

NA trial testing Oral Glucose Tolerance Test in Type 1 Diabetes in 7 participants. Terminated before completion.

Timeline

21 November 2019

Primary endpoint
30 March 2022

30 March 2022

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	7
Start date	21 November 2019
Primary completion	30 March 2022
Estimated completion	30 March 2022
Sites	1 location across United States

Drugs / interventions tested

Oral Glucose Tolerance Test — full drug profile →

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →
De Novo Lipogenesis — all drugs for De Novo Lipogenesis →

Sponsor

Yale University

Who can join

Adults 13 to 22, any sex, with Type 1 Diabetes or De Novo Lipogenesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control (HbA1c \<7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fractional hepatic DNL during the fasting and the postprandial states than youth who achieve targeted glycemic control and lean controls.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth.
Monga Kravetz A, Testerman T, Galuppo B, Graf J, et al · · 2020 · cited 66× · PMID 32561908 · DOI 10.1210/clinem/dgaa382

Verify or expand the search:

Other trials of Oral Glucose Tolerance Test

Trials testing the same drug.

NCT06184373 — Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot · recruiting
NCT06942312 — Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease · enrolling by invitation
NCT05058690 — Artificial Intelligence to Improve Cardiometabolic Risk Evaluation Using CT Scans · NA · not yet recruiting
NCT05867524 — Characterization of Natural IL-6 Inhibition in Healthy Individuals · NA · unknown
NCT05440968 — Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia · NA · unknown

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04101045 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 13 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04101045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing